Zentiva Generics Company Intelligence Report - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/311061

Zentiva Generics Company Intelligence Report

Description:

Zentiva was created through the merger of the Czech company, Léciva, and the Slovak firm Slovakofarma, which was completed in August 2003. The two former companies began selling products under the Zentiva name from the beginning of September 2003.

Zentiva specialises in the development of generics, and holds leading market positions in both the Czech and Slovak Republics. Outside of these two home markets, Zentiva’s most important markets are those of Central and Eastern Europe, and in particular Poland, Romania, Russia, and since 2007, Turkey. The company is establishing new businesses in other territories, including Lithuania, Latvia, Bulgaria and Ukraine.

Zentiva reported sales worth CZK18,377.9 million (US$1,087.4 million) in 2007, up 10.3% over 2007. The increase was driven by the consolidation of Zentiva’s Turkish business. However, net profit fell by 30.4% to CZK1,013 million (US$59.9 million).

Zentiva is now owned by sanofi-aventis. In March 2006, sanofi-aventis acquired a 24.9% stake in Zentiva. The shares were purchased for 430.3 million euros, and have made sanofi-aventis Zentiva’s largest shareholder. Zentiva has since acquired a number of generic products from SA. In June 2008, sanofi-aventis made an unsolicited offer to acquire the entire firm. The bid was improved in September 2008, and completed in 2009.

In June 2007, Zentiva entered the Turkish market with the purchase of a 75% stake in Eczacibasi Generic Pharmaceuticals, a major domestic pharmaceutical supplier in Turkey, from EIS Eczacibasi Ilaç Sanayi ve Ticaret, for EUR 460 million in cash, on a cash and debt-free basis. The seller will retain a 25% stake, which Zentiva will have a right to purchase after a two-year period.

Contents:

EXECUTIVE SUMMARY

INTRODUCTION

PRODUCTS

FINANCIAL RESULTS
Latest fiscal year results, FY08
Zentiva: Full Year Results, Fiscal year to 31st December in CZK millions
Zentiva: Full Year Results, Fiscal year to 31st December in US$ millions
Sales by segment
Zentiva: Full Year Results by Segment, Fiscal year to 31st December in CZK millions
Zentiva: Full Year Results by Segment, Fiscal year to 31st December in US$ millions
Zentiva: Top Selling Brands, fiscal year to 31st December, in CZK millions
Zentiva: Top Selling Brands, fiscal year to 31st December, in US$ millions
Pharmaceutical Sales by Region
Zentiva: Pharmaceutical Results by Region, Fiscal year to 31st December in CZK millions
Zentiva: Full Year Results by Region, Fiscal year to 31st December in US$ millions

MAJOR DEVELOPMENTS
Mergers, acquisitions and agreements
Zentiva acquired by sanofi-aventis
Zentiva completes purchase of Eczacibasi's generic pharmaceuticals business

CONTACT DETAILS

Companies Mentioned

sanofi-aventis Sicomed Litigation Atorvastatin

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/311061

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 12/02/2012 18:31:06

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Zentiva Generics Company Intelligence Report
Web Address:
http://www.researchandmarkets.com/reports/311061
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		€245.00
Electronic (Online Access) - Enterprisewide		€1,595.00
Hard Copy		€245.00 + EUR€ 25.00 Shipping/Handling *
Electronic (Online Access) - Single User		€245.00
Electronic (PDF) - Enterprisewide		€1,595.00

* Shipping/Handling is only charged once per order.

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 12/02/2012 18:31:06

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)